Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) EPS (Weighted Average and Diluted) (2021 - 2026)

Biodesix filings provide 6 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.81 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 46.71% to -$0.81 in Q1 2026 year-over-year; TTM through Mar 2026 was -$2.48, a 38.46% increase, with the full-year FY2025 number at -$4.67, up 29.67% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.81 in Q1 2026 for Biodesix, down from -$0.43 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.08 in Q2 2024 to a low of -$1.52 in Q1 2025.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.34 (2022), compared with a mean of -$0.52.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 91.16% in 2022 and later crashed 1044.44% in 2024.
  • Biodesix's EPS (Weighted Average and Diluted) stood at -$0.33 in 2022, then surged by 72.73% to -$0.09 in 2023, then crashed by 1044.44% to -$1.03 in 2024, then skyrocketed by 58.25% to -$0.43 in 2025, then crashed by 88.37% to -$0.81 in 2026.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.81 (Q1 2026), -$0.43 (Q4 2025), and -$1.16 (Q3 2025) per Business Quant data.